Ocala Oncology Center

Running trials

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Source

• Active, not recruiting

  BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

  NCT06773910· Phase 2· Source

• Recruiting

  A Study of IBI363 in Subjects with Advanced Solid Malignancies

  NCT06281678· Phase 2· Source

• Active, not recruiting

  A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

  NCT05653882· Phase 1· Source

• Active, not recruiting

  A Study of NDI 1150-101 in Patients With Solid Tumors

  NCT05128487· Phase 1/2· Source

• Active, not recruiting

  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

  NCT04561362· Phase 1/2· Source

• Active, not recruiting

  TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

  NCT04485013· Phase 1· Source

• Active, not recruiting

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· Phase 3· Source

• Active, not recruiting

  PhII ICb With/Without Erbitux in MBC Pts

  NCT00248287· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Source

• Completed

  UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

  NCT04382664· Phase 2· Source

• Terminated

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Phase 1· Source

• Completed

  Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

  NCT01454297· Source